The Failure Of Biosimilars In The US: ‘Headline’ News
A Washington Post article on price hikes for Abbvie’s Humira highlights patent ‘thickets’ and anti-biosimilar strategies. But the lack of understanding of the basic concepts of the biosimilar system are a much bigger warning sign about the viability of the pathway.
You may also be interested in...
Current drug pricing legislative effort offers the prospect of a substantial update to 2010 biosimilar law – substantial at least in the list of statutory changes, if not in the potential near term impact on the marketplace.
The latest salvo has been fired in a fierce debate between US healthcare experts on whether US policymakers and payers should give up on biosimilars in favor of price controls on original biologics.
“We’re not going to wait a decade or more for robust biosimilar competition to emerge,” Commissioner Scott Gottlieb says, noting reference biologic sponsors are repeating some of the delay tactics honed in the small molecule space to keep competition at bay.